Alta Life Sciences

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Peptomyc is a biotechnology company established in December 2014, dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a key player in cancer cell survival and proliferation. Founded on the research of Dr. Soucek, Peptomyc aims to address the limitations of conventional cancer therapies, which often fail due to the development of resistance. The company's approach focuses on inhibiting Myc, which is deregulated in a majority of human cancers and is critical for tumor survival. By targeting this oncogene, Peptomyc seeks to enhance treatment efficacy for various cancers, including lung, breast, and brain tumors, ultimately improving patient outcomes. Despite the central role of Myc in cancer, no inhibitors have yet been approved for clinical use, positioning Peptomyc at the forefront of a promising therapeutic opportunity.

Mediktor is a technology company that has developed an advanced pre-diagnosis tool utilizing artificial intelligence and natural language recognition to assist patients in identifying symptoms and potential conditions. The system is designed to facilitate pre-diagnosis, triage, and decision-making support, ultimately transforming healthcare delivery. By empowering patients to make informed decisions based on their initial symptoms, Mediktor aims to reduce barriers to healthcare access. Additionally, the platform enables healthcare providers to effectively manage demand and optimize resources, thereby improving overall medical coverage. By connecting patients with medical professionals within health insurance networks, Mediktor enhances the efficiency and safety of healthcare decisions for hospitals and health systems.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.

Peptomyc is a biotechnology company established in December 2014, dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a key player in cancer cell survival and proliferation. Founded on the research of Dr. Soucek, Peptomyc aims to address the limitations of conventional cancer therapies, which often fail due to the development of resistance. The company's approach focuses on inhibiting Myc, which is deregulated in a majority of human cancers and is critical for tumor survival. By targeting this oncogene, Peptomyc seeks to enhance treatment efficacy for various cancers, including lung, breast, and brain tumors, ultimately improving patient outcomes. Despite the central role of Myc in cancer, no inhibitors have yet been approved for clinical use, positioning Peptomyc at the forefront of a promising therapeutic opportunity.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Accure Therapeutics is a private pharma R&D engine at clinical stage in the CNS field.

SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.

Mediktor is a technology company that has developed an advanced pre-diagnosis tool utilizing artificial intelligence and natural language recognition to assist patients in identifying symptoms and potential conditions. The system is designed to facilitate pre-diagnosis, triage, and decision-making support, ultimately transforming healthcare delivery. By empowering patients to make informed decisions based on their initial symptoms, Mediktor aims to reduce barriers to healthcare access. Additionally, the platform enables healthcare providers to effectively manage demand and optimize resources, thereby improving overall medical coverage. By connecting patients with medical professionals within health insurance networks, Mediktor enhances the efficiency and safety of healthcare decisions for hospitals and health systems.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Peptomyc is a biotechnology company established in December 2014, dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a key player in cancer cell survival and proliferation. Founded on the research of Dr. Soucek, Peptomyc aims to address the limitations of conventional cancer therapies, which often fail due to the development of resistance. The company's approach focuses on inhibiting Myc, which is deregulated in a majority of human cancers and is critical for tumor survival. By targeting this oncogene, Peptomyc seeks to enhance treatment efficacy for various cancers, including lung, breast, and brain tumors, ultimately improving patient outcomes. Despite the central role of Myc in cancer, no inhibitors have yet been approved for clinical use, positioning Peptomyc at the forefront of a promising therapeutic opportunity.